source
- Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureInvestors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.BioSpace · 3h ago↗ source
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpointMerck and Moderna reported that their personalized mRNA cancer vaccine, combined with Merck’s Keytruda, slowed melanoma recurrence in a Phase 3 study. The interim analysis showed a statistically si…